(Press-News.org) Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an experimental model, this type of immunotherapy actually promoted the development of liver cancer, as now reported in the journal Nature.
Liver cancer is the sixth most common type of cancer in the world, but the fourth most common cause of death from cancer. That is mainly due to the fact that liver cancer is often not detected until a late stage. Although various therapies are available to treat advanced-stage disease, they can usually only temporarily halt progression of the disease. Immunotherapies - known as checkpoint inhibitors - are effective in around a quarter of patients. Up to now, it was unclear which patients were likely to benefit from this treatment and which were not.
The development of liver cancer is driven by chronic inflammation, which can be due to chronic hepatitis B or C infection or alcohol abuse. An unhealthy lifestyle can also contribute to development of the disease: too many calories, too little exercise, and excessive body weight lead to fatty liver. In turn, this may result in non-alcoholic steatohepatitis or NASH - a hotbed for liver cancer.
"Fatty liver and NASH are taking on pandemic proportions across the globe," explained Mathias Heikenwälder from the German Cancer Research Center (DKFZ). Heikenwälder, a metabolic specialist, investigated the presumption that the different triggers of cancer-promoting inflammation might influence whether or not immunotherapy is effective.
Mice fed a high-fat diet develop fatty liver and subsequently, like many obese patients, suffer from NASH. In the livers of these animals, the researchers observed an unusually high number of certain T cells carrying the PD1 molecule on their surface (CD8+PD-1+ T cells). Yet these special cells did not protect the animals against the development of liver cancer, but instead appeared to exacerbate the inflammatory tissue damage and surprisingly to actually promote the development of cancer.
The number of harmful T cells increased even further if NASH mice suffering from liver cancer were treated using a checkpoint inhibitor. The liver damage became worse and more tumors occurred. In contrast, in mice without NASH, treatment using checkpoint inhibitors was able to suppress liver cancer, as expected.
"The metabolically activated T cells in the inflamed liver are not only unable to fight liver cancer. They are also autoaggressive and actually drive cancer development. They even increase in number during treatment with the checkpoint inhibitors," Heikenwälder explained.
In collaboration with Percy Knolle and his research team at TU München, Heikenwälder was able to reveal the mechanisms that lead to this autoaggressive disease. The results were also published at the same time in Nature*.
Heikenwälder's results contradict one of the tenets of immunotherapy, according to which the more T cells there are in a tumor, the more likely immunotherapy is to be successful. "That is not true in patients with fatty liver-driven liver cancer," Heikenwälder remarked.
An analysis of various patient cohorts with inflammatory liver disease compared with healthy controls showed that these results are not only relevant to obese mice. In the diseased livers, the researchers found T cells whose molecular profile corresponded to the harmful autoaggressive T cells in the NASH mice. "For us, that was an indication that checkpoint inhibitors might not work in patients with liver cancer caused by inflammatory fatty liver disease," Heikenwälder continued.
In order to support their hypothesis, the research team evaluated several clinical studies on the efficacy of checkpoint inhibitors in liver cancer. A total of around 2,000 patients were enrolled in these studies. In the group of patients with virus-associated tumors, the checkpoint inhibitors improved the cancer survival rate. However, patients with NASH-related liver cancer did not benefit from the treatment. On the contrary: their survival time was considerably shorter than that of patients with virus-associated liver cancer who received exactly the same treatment.
"For the first time, we have identified a biomarker - NASH-related liver cancer - that can help physicians assess whether or not a patient will benefit from immunotherapy," Heikenwälder explained, adding a further important conclusion from the current results: Many thousands of patients with various types of cancer are treated every year using checkpoint inhibitors. Very many of them are overweight - which increases the likelihood of inflammatory fatty liver disease. In these patients, there might be a risk that immunotherapy further activates the autoaggressive T cells in the liver. "That once again underlines how important it is to keep a close eye on liver function in cancer patients being treated with checkpoint inhibitors."
INFORMATION:
Dominik Pfister et al.: NASH precludes anti-tumor surveillance in immunotherapy-treated hepatocellular carcinoma. Nature 2021, DOI: 10.1038/s41586-021-03362-0
* Dudek et al.: Auto-aggressive CXCR6+ 1 CD8 T cells cause liver 2 immune pathology in NASH. Nature 2021, DOI: 10.1038/s41586-021-03362-0
A picture is available for download:
http://www.dkfz.de/de/presse/pressemitteilungen/2021/bilder/210319_DKFZ_Cover_Nature_Leber.jpg
Caption: Inflammatory fatty liver disease and liver cancer - an artistic illustration
Source: Peter von Walter / DKFZ
The heart of any computer, its central processing unit, is built using semiconductor technology, which is capable of putting billions of transistors onto a single chip. Now, researchers from the group of Menno Veldhorst at QuTech, a collaboration between TU Delft and TNO, have shown that this technology can be used to build a two-dimensional array of qubits to function as a quantum processor. Their work, a crucial milestone for scalable quantum technology, was published today in Nature.
Quantum computers have the potential to solve problems that are impossible to address with classical computers. Whereas current ...
HOUSTON ? Overcoming previous technical challenges with single-cell DNA (scDNA) sequencing, a group led by researchers at The University of Texas MD Anderson Cancer Center has developed a novel method for scDNA sequencing at single-molecule resolution. This technique revealed for the first time that triple-negative breast cancers undergo continued genetic copy number changes after an initial burst of chromosome instability.
The findings, published today in Nature, offer an accurate and efficient new approach for sequencing hundreds of individual cancer cells while also providing novel insights into cancer evolution. These insights may explain why treatments are ...
Joint press release by the German Cancer Research Center, University Medicine Mannheim, Heidelberg University Hospital, and the National Center for Tumor Diseases (NCT) Heidelberg
Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors. The vaccine proved to be safe and triggered the desired immune response in the tumor tissue, as the team now reports in the journal Nature.
Diffuse ...
Researchers have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The vaccine product is currently being advanced toward clinical testing. If proven safe and effective, these next-generation influenza vaccines may replace current seasonal options by providing protection against many more strains that current vaccines do not adequately cover.
A study detailing how the new flu vaccines were designed and how they protect mice, ferrets, and nonhuman primates appears in the March 24 edition of the journal Nature. This work was led by researchers at the University of Washington School of Medicine and the Vaccine
Research Center part of the National Institute of Allergy ...
Many children of low-income families across the country do not have access to quality health care. Lack of health care can have a domino effect, affecting educational outcomes in the classroom.
School-based telehealth could offer a sustainable and effective solution, according to a new report in the Journal for Nurse Practitioners by Kathryn King Cristaldi, M.D., the medical director of the school-based telehealth program, and Kelli Garber, the lead advanced practice provider and clinical integration specialist for the program.
The program through the MUSC Health Center for Telehealth has effectively served over 70 schools across the state of South Carolina. Evaluating a child at school via telehealth ...
Probiotics -- those bacteria that are good for your digestive tract -- are short-lived, rarely taking residence or colonizing the gut. But a new study from researchers at the University of California, Davis, finds that in breast milk-fed babies given the probiotic B. infantis, the probiotic will persist in the baby's gut for up to one year and play a valuable role in a healthy digestive system. The study was published in the journal Pediatric Research.
"The same group had shown in a previous study that giving breast milk-fed babies B. infantis had beneficial effects that lasted up to 30 days after supplementation, but this is the first study to show persistent colonization up to 1 year of age," said lead author Jennifer Smilowitz with the UC Davis Department ...
Non-alcoholic steatohepatitis (NASH), often called 'fatty liver hepatitis', can lead to serious liver damage and liver cancer. A team of researchers at the Technical University of Munich (TUM) has discovered that this condition is caused by cells that attack healthy tissue - a phenomenon known as auto-aggression. Their results may help in the development of new therapies to avoid the consequences of NASH.
Fatty liver disease (NASH) is often associated with obesity. However, our understanding of the causes has been very limited. A team working with ...
Rich false memories of autobiographical events can be planted - and then reversed, a new paper has found.
The study highlights - for the first time - techniques that can correct false recollections without damaging true memories. It is published by researchers from the University of Portsmouth, UK, and the Universities of Hagen and Mainz, Germany.
There is plenty of psychological research which shows that memories are often reconstructed and therefore fallible and malleable. However, this is the first time research has shown that false memories of autobiographical events can be undone.
Studying how memories are created, identified ...
Infants prefer baby talk in any language, but particularly when it's in a language they're hearing at home.
A unique study of hundreds of babies involving 17 labs on four continents showed that all babies respond more to infant-directed speech -- baby talk -- than they do to adult-directed speech. It also revealed that babies as young as six months can pick up on differences in language around them.
"We were able to compare babies from bilingual backgrounds to babies from monolingual backgrounds, and what seemed to matter the most was the match between the language they ...
A new study is the first to identify how human brains grow much larger, with three times as many neurons, compared with chimpanzee and gorilla brains. The study, led by researchers at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge, UK, identified a key molecular switch that can make ape brain organoids grow more like human organoids, and vice versa.
The study, published in the journal END ...
